Abstract
C23H26N2O3, triclinic, P1̅ (No. 2), a = 10.6646(19) Å, b = 10.7784(17) Å, c = 11.150(2) Å, α = 67.787(7)°, β = 64.309(7)°, γ = 64.271(7)°, V = 1011.6(3) Å3, Z = 2, Rgt(F) = 0.0502, wRref(F2) = 0.1481, T = 293 K.
The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.
Crystal: | Bronze blocks |
Size: | 0.10 × 0.08 × 0.06 mm |
Wavelength: | Mo Kα radiation (0.71073 Å) |
μ: | 0.8 cm−1 |
Diffractometer, scan mode: | Rigaku R-axis, φ and ω |
2θmax, completeness: | 57°, >99% |
N(hkl)measured, N(hkl)unique, Rint: | 44547, 5072, 0.053 |
Criterion for Iobs, N(hkl)gt: | Iobs > 2 σ(Iobs), 3072 |
N(param)refined: | 256 |
Programs: | Rigaku [9], SHELX [10], ORTEP [11], Platon [12] |
Atom | x | y | z | Uiso*/Ueq |
---|---|---|---|---|
O1 | 0.35602(16) | −0.07674(14) | 0.90803(13) | 0.0767(5) |
O2 | 0.72921(12) | 0.47509(12) | 0.36865(10) | 0.0525(4) |
O3 | 0.85324(13) | 0.48429(13) | 0.52280(11) | 0.0572(4) |
N1 | 0.83849(13) | 0.43732(14) | 0.78758(12) | 0.0467(4) |
N2 | 0.78787(15) | 0.63576(15) | 0.93081(13) | 0.0551(5) |
C1 | 0.39093(17) | 0.16858(16) | 0.57632(15) | 0.0462(5) |
C2 | 0.27926(17) | 0.10499(16) | 0.59942(15) | 0.0461(5) |
C3 | 0.2007(2) | 0.1327(2) | 0.51526(18) | 0.0639(7) |
C4 | 0.1036(2) | 0.0617(2) | 0.5565(2) | 0.0750(8) |
C5 | 0.0817(2) | −0.0360(2) | 0.6806(2) | 0.0729(8) |
C6 | 0.1574(2) | −0.06358(18) | 0.76599(19) | 0.0611(6) |
C7 | 0.25665(17) | 0.00772(15) | 0.72369(16) | 0.0467(5) |
C8 | 0.35036(18) | −0.00220(16) | 0.79465(16) | 0.0507(5) |
C9 | 0.43529(16) | 0.09651(15) | 0.70393(14) | 0.0440(4) |
C10 | 0.52874(17) | 0.11134(16) | 0.74342(15) | 0.0474(5) |
C11 | 0.61842(16) | 0.20355(16) | 0.67922(15) | 0.0440(4) |
C12 | 0.68997(17) | 0.20876(16) | 0.75507(15) | 0.0470(5) |
C13 | 0.77119(17) | 0.29910(16) | 0.70493(15) | 0.0462(5) |
C14 | 0.77934(16) | 0.39021(16) | 0.57557(15) | 0.0436(5) |
C15 | 0.71168(16) | 0.38373(16) | 0.49535(14) | 0.0427(4) |
C16 | 0.63320(16) | 0.29172(16) | 0.54642(14) | 0.0437(5) |
C17 | 0.67428(19) | 0.46372(18) | 0.27885(16) | 0.0547(5) |
C18 | 0.85842(19) | 0.29538(18) | 0.78309(17) | 0.0533(6) |
C19 | 0.95267(17) | 0.43322(18) | 0.83025(17) | 0.0516(5) |
C20 | 0.93170(18) | 0.57806(18) | 0.83613(16) | 0.0537(5) |
C21 | 0.67330(18) | 0.64073(19) | 0.88984(18) | 0.0603(6) |
C22 | 0.69325(18) | 0.49664(19) | 0.88230(17) | 0.0569(6) |
C23 | 0.7679(3) | 0.7755(2) | 0.9382(2) | 0.0790(8) |
H1A | 0.34800 | 0.27030 | 0.56660 | 0.0550* |
H1B | 0.47470 | 0.14870 | 0.49530 | 0.0550* |
H3 | 0.21370 | 0.19880 | 0.43180 | 0.0770* |
H3O | 0.86650 | 0.49570 | 0.58460 | 0.0860* |
H4 | 0.05150 | 0.07970 | 0.49990 | 0.0900* |
H5 | 0.01550 | −0.08320 | 0.70640 | 0.0880* |
H6 | 0.14250 | −0.12840 | 0.85010 | 0.0730* |
H10 | 0.53800 | 0.05190 | 0.82720 | 0.0570* |
H12 | 0.68300 | 0.14970 | 0.84220 | 0.0560* |
H16 | 0.58920 | 0.28760 | 0.49260 | 0.0520* |
H17A | 0.71650 | 0.36830 | 0.26770 | 0.0820* |
H17B | 0.70010 | 0.52730 | 0.19140 | 0.0820* |
H17C | 0.56920 | 0.48790 | 0.31680 | 0.0820* |
H18A | 0.82850 | 0.24000 | 0.87590 | 0.0640* |
H18B | 0.96190 | 0.24870 | 0.74050 | 0.0640* |
H19A | 1.04870 | 0.39720 | 0.76610 | 0.0620* |
H19B | 0.94900 | 0.36940 | 0.91980 | 0.0620* |
H20A | 1.00780 | 0.57260 | 0.86540 | 0.0640* |
H20B | 0.94080 | 0.64060 | 0.74550 | 0.0640* |
H21A | 0.67560 | 0.70570 | 0.80100 | 0.0720* |
H21B | 0.57800 | 0.67600 | 0.95520 | 0.0720* |
H22A | 0.68280 | 0.43360 | 0.97270 | 0.0680* |
H22B | 0.61740 | 0.50380 | 0.85180 | 0.0680* |
H23A | 0.77630 | 0.83830 | 0.84900 | 0.1190* |
H23B | 0.84190 | 0.76870 | 0.96960 | 0.1190* |
H23C | 0.67220 | 0.81150 | 1.00080 | 0.1190* |
Source of material
The mixture of 2-(4-hydroxy-3-methoxybenzylidene)-2,3-dihydroinden-1-one (21 mmol), paraformaldehyde (25 mmol) and N-methyl piperazine (21 mmol) was heated in 15 mL of acetonitrile (393 K) for 10 min. The product was purified by crystallization firstly from methanol-hexane and then from chloroform-hexane. [Yield: 40%, mp.: 471–473 K]. 1H NMR (400 MHz, CDCl3, p.p.m.) δ 7.87 (d, 1H, Ar—H, J = 7.7 Hz, indanone), 7.60–7.53 (m, 3H, Ar—H, indanone, vinylic-H), 7.40 (bt, 1H, Ar—H, J = 7.1 Hz, indanone), 6.97 (s, 1H, Ar—H), 7.11 (s, 1H, Ar—H), 3.98 (s, 2H, 3-CH2, indanone), 3.94 (s, 3H, –OCH3), 3.79 (s, 2H, Ar—CH2N–), 3.00–2.30 (m, 8H, CH2-piperazine), 2.29 (s, 3H, –N—CH3); 13C NMR (100 MHz, CDCl3, p.p.m.) δ 194.4, 149.8, 149.5, 148.4, 138.5, 134.6, 134.5, 132.0, 127.8, 126.7, 126.3, 124.5, 124.4, 121.7, 113.7, 61.3, 56.2, 55.0, 52.7, 46.1, 32.6; Mass spectrum: 379.20 (M+ + 1); HRMS (ESI-MS) Calc.: 379.2022 for C23H27N2O3 [M + H]+, Found: 379.2025 [1].
Experimental details
H atom were placed in calculated positions with O—H = 0.82 Å, C—H = 0.93–0.96 Å, and refined using a riding model with Uiso(H) = 1.2Ueq(C) for the aromatic and methylene H atoms and Uiso(H) = 1.5Ueq(C,O) for the methyl and hydroxyl H atoms.
Discussion
Mannich bases have several biological activities such as antimicrobial [2], antifungal [3], anticonvulsant [4], anti-inflammatory [5], and cytotoxic/anticancer [6, 7] activities. The title Mannich base, 2-[4-hydroxy-5-methoxy-3-(4-methyl-piperazin-1-ylmethyl)-benzylidene]-indan-1-one (cf. the figure) can be concluded from the figure was synthesized starting from 2-(4-hydroxy-3-methoxybenzylidene)-indan-1-one, and was tested as inhibitors of the zinc metalloenzyme cytosolic human carbonic anhydrase (hCA I, and II) isoforms. The title compound is a strong hCA I (Ki: 484.02 ± 30.30 nM) and II inhibitor (Ki: 526.30 ± 112.9 nM).
In the title compound, the piperazine ring (N1/N2/C19—C22) adopts a chair conformation with the puckering parameters [8] of QT = 0.5697(19) Å, θ = 0.0(2)° and φ = 82(12)°, respectively. The 2,3-dihydro-1H-indene ring system (C1—C9) is essentially planar [the puckering parameters are Q(2) = 0.007(2) Å and φ(2) = 20(16)°] and its mean plane makes a dihedral angle of 9.27(7)° with the central benzene ring (C11—C16). The intramolecular O3—H3O⋯N1 hydrogen bonds stabilizes the molecular conformation of the title compound. In the crystal, molecules are linked by weak C—H⋯O, C—H⋯N and C—H⋯π interactions.
Acknowledgements
The authors are indebted to the Department of Chemistry, Atatürk University, Erzurum, Turkey, for use of the X-ray diffractometer purchased under grant No.2003/219 of the University Research Fund.
References
1 Tugrak, M.; Yamali, C.; Sakagami, H.; Gul, H. I.: Synthesis of mono Mannich bases of 2-(4-hydroxybenzylidene)-2,3-dihydroinden-1-one and evaluation of their cytotoxicities. J. Enzyme Inhib. Med. Chem. 6 (2015) 1–6.10.3109/14756366.2015.1070263Search in Google Scholar PubMed
2 Gul, H. I.; Sahin, F.; Gul, M.; Ozturk, S.; Yerdelen, K. O.: Evaluation of antimicrobial activities of several Mannich bases and their derivatives. Arch. Pharm. 338 (2005) 335–338.10.1002/ardp.200400962Search in Google Scholar PubMed
3 Mete, E.; Gul, H. I.; Bilginer, S.; Algul, O.; Topaloglu, M. E.; Gulluce, M.; Kazaz, C.: Synthesis and antifungal evaluation of 1-aryl-2-dimethyl-aminomethyl-2-propen-1-one hydrochlorides. Molecules 16 (2011) 4660–4671.10.3390/molecules16064660Search in Google Scholar PubMed PubMed Central
4 Gul, H. I.; Calls, U.; Ozturk, Z.; Tutar, E.; Calikiran, L.: Evaluation of anticonvulsant activities of bis(3-aryl-3-oxo-propyl) ethylamine hydrochlorides and 4-aryl-3-arylcarbonyl-1-ethyl-4-piperidinol hydrochlorides. Arzneimittelforschung 57 (2007) 133–136.10.1055/s-0031-1296595Search in Google Scholar PubMed
5 Suleyman, H.; Gul, H. I.; Gul, M.; Alkan, M.; Gocer, F.: Anti-inflammatory activity of bis(3-aryl-3-oxo-propyl)methylamine hydrochloride in Rat. Biol. Pharm. Bull. 30 (2007) 63–67.10.1248/bpb.30.63Search in Google Scholar PubMed
6 Bilginer, S.; Gul, H. I.; Mete, E.; Das, U.; Sakagami, H.; Umemura, N.; Dimmock, J. R.: 1-(3-Aminomethyl-4-hydroxyphenyl)-3-pyridinyl-2-propen-1-ones: a novel group of tumour-selective cytotoxins. J. Enzyme Inhib. Med. Chem. 28 (2013) 974–980.10.3109/14756366.2012.700927Search in Google Scholar PubMed
7 Yerdelen, K. O.; Gul, H. I.; Sakagami, H.; Umemura, N.; Sukuroglu, M.: Synthesis and cytotoxic activities of a curcumin analogue and its bis-Mannich derivatives. Lett. Drug. Des. Discov. 12 (2015) 643–649.10.2174/1570180812666150213225134Search in Google Scholar
8 Cremer, D.; Pople, J. A.: General definition of ring puckering coordinates. J. Am. Chem. Soc. 97 (1975) 1354–1358.10.1021/ja00839a011Search in Google Scholar
9 Rigaku/MSC: CrystalClear. Rigaku/MSC, The Woodlands, Texas, USA, 2005.Search in Google Scholar
10 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar PubMed
11 Farrugia, L. J.: ORTEP-3 for Windows a version of ORTEP III with a Graphical User Interface (GUI). J. Appl. Crystallogr. 45 (2012) 849–854.10.1107/S0021889897003117Search in Google Scholar
12 Spek, A. L: Structure validation in chemical crystallography. J. Appl. Cryst. 36 (2003) 7–13.10.1107/S090744490804362XSearch in Google Scholar PubMed PubMed Central
©2016 Mehtap Tugrak et al., published by De Gruyter.
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.